Erythropoietin protects critically perfused flap tissue

Annals of Surgery

Volumn 248, Issue 6, 2008, Pages 919-927

  Rezaeian, Farid ^a   Wettstein, Reto ^a   Amon, Michaela ^a   Scheuer, Claudia ^b   Schramm, Renè ^b   Menger, Michael D ^b   Pittet, Brigitte ^a   Harder, Yves ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; INDUCIBLE NITRIC OXIDE SYNTHASE; SODIUM CHLORIDE; VASCULOTROPIN; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL MODEL; APOPTOSIS; ARTERY DILATATION; ARTICLE; C57BL 6 MOUSE; CAPILLARY DENSITY; CELL INTERACTION; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIUM CELL; FLUORESCENCE MICROSCOPY; ISCHEMIA; ISCHEMIC PRECONDITIONING; LEUKOCYTE; LEUKOCYTE ADHERENCE; MICROVASCULAR ISCHEMIA; MOUSE; MYOCUTANEOUS FLAP; NONHUMAN; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROTECTION; REPEATED DRUG DOSE; TISSUE NECROSIS; TISSUE PERFUSION; TISSUE SURVIVAL; UPREGULATION; ANIMAL; ARTERIOLE; BLOOD FLOW; C57BL MOUSE; CAPILLARY; LESIONS AND DEFECTS; METABOLISM; METHODOLOGY; MICROCIRCULATION; NECROSIS; PATHOLOGY; PHYSIOLOGY; PLASTIC SURGERY; VASCULARIZATION; WESTERN BLOTTING;

ANIMALS; ARTERIOLES; BLOTTING, WESTERN; CAPILLARIES; DILATATION, PATHOLOGIC; ERYTHROPOIETIN; MICE; MICE, INBRED C57BL; MICROCIRCULATION; MICROSCOPY, FLUORESCENCE; NECROSIS; NEOVASCULARIZATION, PHYSIOLOGIC; NITRIC OXIDE SYNTHASE TYPE II; REGIONAL BLOOD FLOW; SURGICAL FLAPS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 58149377014     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e31818f678e     Document Type: Article

References (50)

1. Giudicelli R, Thomas P, Massard G, et al. Tracheobronchial healing after lung and heart-lung transplantation. A critical review of 64 anastomoses. The Joint Marseille-Montreal Lung Transplant Program. Eur J Cardiothorac Surg. 1993;7:453-456.
2. Khouri RK, Cooley BC, Kunselman AR, et al. A prospective study of microvascular free-flap surgery and outcome. Plast Reconstr Surg. 1998;102:711-721.
3. Wettstein R, Schürch R, Banic A, et al. Review of 197 consecutive free flap reconstruction in the lower extremity. J Plast Reconstr Aesthet Surg. 2008;61:772-776.
4. Menger MD, Rucker M, Vollmar B. Capillary dysfunction in striated muscle ischemia/reperfusion: on the mechanisms of capillary "no-re- flow." Shock. 1997;8:2-7.
5. Harder Y, Amon M, Georgi M, et al. Evolution of a "falx lunatica" in demarcation of critically ischemic myocutaneous tissue. Am J Physiol Heart Circ Physiol. 2005;288:H1224-H1232.
6. Vollmar B, Richter S, Menger MD. Liver ischemia/reperfusion induces an increase of microvascular leukocyte flux, but not heterogeneity of leukocyte trafficking. Liver. 1997;17:93-98.
7. Amon M, Menger MD, Vollmar B. Heme oxygenase and nitric oxide synthase mediate cooling-associated protection against TNF-alpha-in- duced microcirculatory dysfunction and apoptotic cell death. Faseb J. 2003;17:175-185.
8. Hashimoto I, Nakanishi H, Shono Y, et al. The features of thrombus in a microvessel injury model and the antithrombotic efficacy of heparin, urokinase, and prostaglandin E1. Plast Reconstr Surg. 2003;111:2307-2314.
9. Ashrafpour H, Huang N, Neligan PC, et al. Vasodilator effect and mechanism of action of vascular endothelial growth factor in skin vasculature. Am J Physiol Heart Circ Physiol. 2004;286:H946-H954.
10. Erni D, Wettstein R, Schramm S, et al. Normovolemic hemodilution with Hb vesicle solution attenuates hypoxia in ischemic hamster flap tissue. Am J Physiol Heart Circ Physiol. 2003;284:H1702-H1709.
11. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986; 74:1124-1136.
12. Reinisch JF. The pathophysiology of skin flap circulation. The delay phenomenon. Plast Reconstr Surg. 1974;54:585-598.
13. Harder Y, Amon M, Schramm R, et al. Heat shock preconditioning reduces ischemic tissue necrosis by heat shock protein (HSP)-32-medi- ated improvement of the microcirculation rather than induction of ischemic tolerance. Ann Surg. 2005;242:869-878; discussion 878-879.
14. Rücker M, Schafer T, Roesken F, et al. Local heat-shock priming- induced improvement in microvascular perfusion in osteomyocutaneous flaps is mediated by heat-shock protein 32. Br J Surg. 2001;88:450-457.
15. Kubulus D, Amon M, Roesken F, et al. Experimental cooling-induced preconditioning attenuates skin flap failure. Br J Surg. 2005;92:1432-1438.
16. Uhl E, Barker JH, Bondar I, et al. Improvement of skin flap perfusion by subdermal injection of recombinant human basic fibroblast growth factor. Ann Plast Surg. 1994;32:361-365; discussion 365-366.
17. Harder Y, Contaldo C, Klenk J, et al. Preconditioning with monophos- phoryl lipid A improves survival of critically ischemic tissue. Anesth Analg. 2005;100:1786-1792.
18. Mulcahy L. The erythropoietin receptor. Semin Oncol. 2001;28(suppl 8):19-23.
19. Erslev A. Humoral regulation of red cell production. Blood. 1953;8: 349-357.
20. Brines ML, Ghezzi P, Keenan S, et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA. 2000;97:10526-10531.
21. Haroon ZA, Amin K, Jiang X, et al. A novel role for erythropoietin during fibrin-induced wound-healing response. Am J Pathol. 2003;163: 993-1000.
22. Yatsiv I, Grigoriadis N, Simeonidou C, et al. Erythropoietin is neuro- protective, improves functional recovery, and reduces neuronal apopto- sis and inflammation in a rodent model of experimental closed head injury. Faseb J. 2005;19:1701-1703.
23. Ribatti D, Presta M, Vacca A, et al. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood. 1999;93:2627-2636.
24. Calvillo L, Latini R, Kajstura J, et al. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci USA. 2003;100:4802-4806.
25. Patel NS, Cuzzocrea S, Chatterjee PK, et al. Reduction of renal isch- emia-reperfusion injury in 5-lipoxygenase knockout mice and by the 5-lipoxygenase inhibitor zileuton. Mol Pharmacol. 2004;66:220-227.
26. Sepodes B, Maio R, Pinto R, et al. Recombinant human erythropoietin protects the liver from hepatic ischemia-reperfusion injury in the rat. TransplInt. 2006;19:919-926.
27. Holstein JH, Menger MD, Scheuer C, et al. Erythropoietin (EPO): EPO-receptor signaling improves early endochondral ossification and mechanical strength in fracture healing. Life Sci. 2007;80:893-900.
28. Buemi M, Galeano M, Sturiale A, et al. Recombinant human erythro- poietin stimulates angiogenesis and healing of ischemic skin wounds. Shock. 2004;22:169-173.
29. Buemi M, Vaccaro M, Sturiale A, et al. Recombinant human erythro- poietin influences revascularization and healing in a rat model of random ischaemic flaps. Acta Derm Venereol. 2002;82:411-417.
30. Harder Y, Amon M, Erni D, et al. Evolution of ischemic tissue injury in a random pattern flap: a new mouse model using intravital microscopy. J Surg Res. 2004;121:197-205.
31. Lehr HA, Leunig M, Menger MD, et al. Dorsal skinfold chamber technique for intravital microscopy in nude mice. Am J Pathol. 1993; 143:1055-1062.
32. Klyscz T, Junger M, Jung F, et al. [Cap image-a new kind of computer- assisted video image analysis system for dynamic capillary microscopy.] Biomed Tech (Berl). 1997;42:168-175.
33. Gross JF, Aroesty J. Mathematical models of capillary flow: a critical review. Biorheology. 1972;9:225-264.
34. Menger MD, Pelikan S, Steiner D, et al. Microvascular ischemia- reperfusion injury in striated muscle: significance of "reflow paradox." Am J Physiol. 1992;263(6 Pt 2):H1901-H1906.
35. Lowry OH, Rosebrough NJ, Farr AL, et al. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265-275.
36. Ateshkadi A, Johnson CA, Oxton LL, et al. Pharmacokinetics of intra- peritoneal, intravenous, and subcutaneous recombinant human erythro- poietin in patients on continuous ambulatory peritoneal dialysis. Am J Kidney Dis. 1993;21:635-642.
37. Lai IR, Ma MC, Chen CF, et al. The protective role of heme oxygen- ase-1 on the liver after hypoxic preconditioning in rats. Transplantation. 2004;77:1004-1008.
38. Santhanam AV, Smith LA, Nath KA, et al. In vivo stimulatory effect of erythropoietin on endothelial nitric oxide synthase in cerebral arteries. Am J Physiol Heart Circ Physiol. 2006;291:H781-H786.
39. Contaldo C, Meier C, Elsherbiny A, et al. Human recombinant erythro- poietin protects the striated muscle microcirculation of the dorsal skin- fold from postischemic injury in mice. Am JPhysiol Heart Circ Physiol. 2007;293:H274-H283.
40. Galeano M, Altavilla D, Bitto A, et al. Recombinant human erythropoi- etin improves angiogenesis and wound healing in experimental burn wounds. Crit Care Med. 2006;34:1139 -1146.
41. Sano H, Hosokawa K, Kidoya H, et al. Negative regulation of VEGF- induced vascular leakage by blockade of angiotensin II type 1 receptor. Arterioscler Thromb Vasc Biol. 2006;26:2673-2680.
42. Schoch HJ, Fischer S, Marti HH. Hypoxia-induced vascular endothelial growth factor expression causes vascular leakage in the brain. Brain. 2002;125(Pt 11):2549-2557.
43. Wang L, Zhang Z, Wang Y, et al. Treatment of stroke with erythropoi- etin enhances neurogenesis and angiogenesis and improves neurological function in rats. Stroke. 2004;35:1732-1737.
44. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339: 584 -590.
45. Jaar B, Denis A, Viron B, et al. Effects of long-term treatment with recombinant human erythropoietin on physiologic inhibitors of coagulation. Am J Nephrol. 1997;17:399-405.
46. Ehrenreich H, Hasselblatt M, Dembowski C, et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med. 2002;8: 495-505.
47. Saray A, Ozakpinar R, Koc C, et al. Effect of chronic and short-term erythropoietin treatment on random flap survival in rats: an experimental study. Laryngoscope. 2003;113:85-89.
48. Lipsic E, van der Meer P, Henning RH, et al. Timing of erythropoietin treatment for cardioprotection in ischemia/reperfusion. J Cardiovasc Pharmacol. 2004;44:473-479.
49. Burger D, Lei M, Geoghegan-Morphet N, et al. Erythropoietin protects cardiomyocytes from apoptosis via up-regulation of endothelial nitric oxide synthase. Cardiovasc Res. 2006;72:51-59.
50. Kim EK, Hong JP. The effect of recombinant human erythropoietin on ischemia-reperfusion injury: an experimental study in a rat TRAM flap model. Plast Reconstr Surg. 2007;120:1774-1781.